Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A(2023) Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results EJHaem, 4(4), 1117-1131 DOI 10.1002/jha2.743, PubMed 38024633
Schjesvold FH, Ludwig H, Mateos MV, Larocca A, Abdulhaq H, Norin S, Thuresson M, Bakker NA, Richardson PG, Sonneveld P(2023) Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study Eur J Haematol(in press) DOI 10.1111/ejh.14127, PubMed 37968873
van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Grasso M, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro Met al.(2023) Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study Lancet Oncol, 24(10), 1119-1133 DOI 10.1016/S1470-2045(23)00405-9, PubMed 37717583
